EU Pilot Shows Single Drug Development Plan Can Meet Both Regulator And HTA Needs
This article was originally published in SRA
Executive Summary
The EU's pilot exercise in offering drug developers parallel regulatory and health technology assessment (HTA) advice has shown that in most cases a single trial design or drug development plan can be agreed that meets the requirements of the two parties without blurring their respective remits, says a new report from the European Medicines Agency1.